Predicting response to PD-1 immunotherapy in advanced lung cancer patients
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with Non Small Cell Lung Cancer Mass Tissue Imaging HyperIONTM
This study is trying to find out if certain markers in tumors can help predict how well advanced lung cancer patients will respond to a specific immunotherapy treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Drugs / interventions | pembrolizumab, immunotherapy |
| Locations | 1 site (Brest) |
| Trial ID | NCT04886401 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers that can predict the response and toxicity of PD-1 immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). By analyzing tumor microenvironments using advanced imaging techniques, the study seeks to uncover immunophenotypic signatures associated with treatment outcomes. Patients who received pembrolizumab as a first-line treatment between January 2017 and December 2019 will be evaluated based on their response and adverse effects. The findings could lead to improved patient selection and treatment strategies in immuno-oncology.
Who should consider this trial
Good fit: Ideal candidates include adult patients with advanced NSCLC who have a PD-L1 tumor proportion score of 50% or greater and received their first dose of pembrolizumab between January 2017 and December 2019.
Not a fit: Patients with autoimmune diseases, prior exposure to immunotherapy, or those who received their first dose of pembrolizumab after December 2019 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict which patients will benefit from PD-1 immunotherapy, leading to more personalized and effective treatment plans.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for immunotherapy response, but this specific approach using multiplex imaging is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients * Advanced NSCLC with PD-L1 TPS of 50% or greater * Administration of first line pembrolizumab between January 2017 \& December 2019 Exclusion Criteria: * Auto-immune disease * Prior exposure to immunotherapy * First dose pembrolizumab administered after December 2019
Where this trial is running
Brest
- CHRU de Brest — Brest, France (Recruiting)
Study contacts
- Principal investigator: Margaux GEIER, MD — Chru Brest
- Study coordinator: Margaux GEIER, MD
- Email: margaux.geier@chu-brest.fr
- Phone: 02 30 33 80 30
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.